Literature DB >> 20559997

Looking for hypertrophic cardiomyopathy in the community: why is it important?

Stefano Nistri1, Iacopo Olivotto, Francesca Girolami, Francesca Torricelli, Franco Cecchi, Magdi H Yacoub.   

Abstract

Hypertrophic cardiomyopathy (HCM) is an epidemiologically relevant, worldwide spread condition which is frequently perceived as a rare disease. This misconception might be supported by some characteristics of HCM such as its incomplete penetrance and variable age at onset and by the fact that many patients remain asymptomatic for a long course of the disease and are thus unlikely to seek for medical evaluation. Multiple evidences suggest that early diagnosis of HCM is important, not only because it allows the patients to be addressed to appropriate diagnostic work-out and to adequate therapeutical options but because it may trigger the screening of family members with the potential of further, new diagnosis of HCM in previously unsuspected individuals. Increased awareness of the disease among physicians working in community-based hospitals and in outpatients facilities, and a facilitated communication and access to tertiary referral centers, will result into a wider knowledge of the spectrum of the disease, a better access to the state-of-the-art management options for patients, and to a more diffuse practice of genetic evaluation of HCM families.

Entities:  

Mesh:

Year:  2009        PMID: 20559997     DOI: 10.1007/s12265-009-9135-4

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  30 in total

1.  Hypertrophic cardiomyopathy: an important global disease.

Authors:  Barry J Maron
Journal:  Am J Med       Date:  2004-01-01       Impact factor: 4.965

2.  Single-gene mutations and increased left ventricular wall thickness in the community: the Framingham Heart Study.

Authors:  Hiroyuki Morita; Martin G Larson; Scott C Barr; Ramachandran S Vasan; Christopher J O'Donnell; Joel N Hirschhorn; Daniel Levy; Diane Corey; Christine E Seidman; J G Seidman; Emelia J Benjamin
Journal:  Circulation       Date:  2006-06-05       Impact factor: 29.690

3.  Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program.

Authors:  Domenico Corrado; Cristina Basso; Andrea Pavei; Pierantonio Michieli; Maurizio Schiavon; Gaetano Thiene
Journal:  JAMA       Date:  2006-10-04       Impact factor: 56.272

4.  Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy.

Authors:  Carsten Rickers; Norbert M Wilke; Michael Jerosch-Herold; Susan A Casey; Prasad Panse; Neeta Panse; Jochen Weil; Andrey G Zenovich; Barry J Maron
Journal:  Circulation       Date:  2005-08-09       Impact factor: 29.690

5.  Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention.

Authors:  Barry J Maron; Jeffrey A Towbin; Gaetano Thiene; Charles Antzelevitch; Domenico Corrado; Donna Arnett; Arthur J Moss; Christine E Seidman; James B Young
Journal:  Circulation       Date:  2006-03-27       Impact factor: 29.690

6.  Comparison of U.S. and Italian experiences with sudden cardiac deaths in young competitive athletes and implications for preparticipation screening strategies.

Authors:  Barry J Maron; Tammy S Haas; Joseph J Doerer; Paul D Thompson; James S Hodges
Journal:  Am J Cardiol       Date:  2009-05-18       Impact factor: 2.778

7.  Screening for hypertrophic cardiomyopathy in young athletes.

Authors:  D Corrado; C Basso; M Schiavon; G Thiene
Journal:  N Engl J Med       Date:  1998-08-06       Impact factor: 91.245

8.  Use of tissue Doppler to distinguish discrete upper ventricular septal hypertrophy from obstructive hypertrophic cardiomyopathy.

Authors:  Annabel Chen-Tournoux; Michael A Fifer; Michael H Picard; Judy Hung
Journal:  Am J Cardiol       Date:  2008-03-17       Impact factor: 2.778

9.  Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases.

Authors:  Perry Elliott; Bert Andersson; Eloisa Arbustini; Zofia Bilinska; Franco Cecchi; Philippe Charron; Olivier Dubourg; Uwe Kühl; Bernhard Maisch; William J McKenna; Lorenzo Monserrat; Sabine Pankuweit; Claudio Rapezzi; Petar Seferovic; Luigi Tavazzi; Andre Keren
Journal:  Eur Heart J       Date:  2007-10-04       Impact factor: 29.983

10.  Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984.

Authors:  M B Codd; D D Sugrue; B J Gersh; L J Melton
Journal:  Circulation       Date:  1989-09       Impact factor: 29.690

View more
  1 in total

1.  Clinical Characteristics and Healthcare Resource Utilization among Patients with Obstructive Hypertrophic Cardiomyopathy Treated in a Range of Settings in the United States.

Authors:  Michael Butzner; Ethan Rowin; Amin Yakubu; Josiah Seale; Laura A Robertson; Phil Sarocco; Martin S Maron
Journal:  J Clin Med       Date:  2022-07-04       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.